Logo KMS TEAM
Precise execution

MC Services is...

Client News

… an international Corporate Communications and Investor Relations firm providing high-level consultancy with targeted services and support for transaction-oriented assignments throughout Europe and the United States.

read more

 

MC Services hosts the press lounge at the German Equity Forum 2015
MC Services AG will, for the third year in a row, sponsor the German Equity Forum, and will provide the event's press lounge, an exclusive working and communications facility with interview areas and workstations for companies, investors, media partners and journalists. Furthermore, MC Services will present a significant number of companies and clients on the healthcare/biotech panels and moderate Q&A sessions following the presentations.
The German Equity Forum is recognized as Europe’s most important capital markets event for corporate finance. The forum provides an information and networking platform to the entire financial services industry: entrepreneurs, investors and analysts. This year the forum will take place from Monday, 23rd November to Wedensday, 25 November in Frankfurt. For the first time, the event will be held at the Sheraton Frankfurt Airport Hotel & Conference Center.


Please also follow us on Twitter (@MCServicesAG; #MCPressLounge; #EKF15)

read more

 

MC Services’summer team meeting in Düsseldorf
This year, the MC Services Team’s summer gathering took place in Düsseldorf. The teams from Munich, Düsseldorf and London learned how to BBQ, which provided a great opportunity to meet and catch up with all our colleagues. Now, we are prepared for the summer! Impressions from the Team Event can be viewed on Facebook.


Please also follow us on Twitter (@MCServicesAG)

read more

MorphoSys's Partner Heptares Initiates Proprietary Therapeutic Antibody Program against a GPCR Target

www.morphosys.com

Basis for new treatment options for a fatal leukemia in children revealed

www.alacris.de

R-Biopharm and Apogenix Enter Cooperation to Develop Companion Diagnostic Tests for Apogenix' Immuno-Oncology Candidate APG101

www.r-biopharm.com

Apogenix Enters into Cooperation with R-Biopharm to Develop Companion Diagnostic Tests for Immuno-Oncology Candidate APG101

www.apogenix.de

MorphoSys AG Reports Results for the First Six Months of 2015

www.motifbio.com

PAION BEENDET REMIMAZOLAM KNOW-HOW UND TECHNOLOGIE-TRANSFER VON ONO

www.paion.com

FDA QIDP Designation for Motif's Lead Antibiotic Candidate Iclaprim for ABSSSI

www.motifbio.com

MorphoSys Announces Clinical Milestone in Blood Disorders Program

www.morphosys.com

Final condition of £22 million placing satisfied with FDA QIDP Designation for iclaprim

www.motifbio.com

CEVEC raises € 4.5 million in a financing round to commercialize its leading CAP® based technologies

www.cevec.com